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Abstract
Background: Transarterial chemoembolization (TACE) therapy is an effective locoregional treatment in
hepatocellular cancer (HCC) patients. For early modification of therapy, markers predicting therapy response are
urgently required.
Methods: Here, sera of 50 prospectively and consecutively included HCC patients undergoing 71 TACE therapies
were taken before and 3 h, 6 h and 24 h after TACE application to analyze concentrations of circulating
nucleosomes, cytokeratin-19 fragments (CYFRA 21-1), alpha fetoprotein (AFP), C-reactive protein (CRP) and several
liver biomarkers, and to compare these with radiological response to therapy.
Results: While nucleosomes, CYFRA 21-1, CRP and some liver biomarkers increased already 24 h after TACE,
percental changes of nucleosome concentrations before and 24 h after TACE and pre- and posttherapeutic values
of AFP, gamma-glutamyl-transferase (GGT) and alkaline phosphatase (AP) significantly indicated the later therapy
response (39 progression versus 32 no progression). In multivariate analysis, nucleosomes (24 h), AP (24 h) and
TACE number were independent predictive markers. The risk score of this combination model achieved an AUC of
81.8% in receiver operating characteristic (ROC) curves and a sensitivity for prediction of non-response to therapy
of 41% at 97% specificity, and of 72% at 78% specificity.
Conclusion: Circulating nucleosomes and liver markers are valuable tools for early estimation of the efficacy of
TACE therapy in HCC patients.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the third most common
cause of cancer-related death with approximately 500,000
deaths each year [1]. In recent years, incidence of HCC
has been increasing in western countries [2]. The major
risk factors of HCC are liver cirrhosis, alcohol abuse, and
hepatitis B and C virus infections [3-5]. Most patients
have at least two concomitant diseases, such as chronic
liver disease and HCC, while complex interactions
between these have major implications for diagnosis,
prognosis and management of HCC. The clinical course
of patients is determined by both liver function and the
extent of HCC. Curative therapy options include resec-
tion, liver transplantation and radiofrequency ablation
(RFA). However, these are often not applicable due to
advanced tumor stage [6,7].
The best therapy option available for HCC patients
who cannot be treated curably is transarterial chemoem-
bolization (TACE), where iodized oil mixed with antican-
cer agents and an embolic material is administered
through the hepatic artery. Iodized oil is used as a vehicle
to transport the anticancer drug, while the embolic mate-
rial enhances the antitumor effect of the anticancer drug.
N o r m a ll i v e rt i s s u ei ss p a r e da sb l o o ds u p p l yi sm a i n l y
delivered via the portal vein, whereas the tumor cells are
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is a minimally invasive procedure with a demonstrated
ability to reduce systemic toxicity, increase local effects
and improve overall therapeutic results, particularly in
the treatment of unresectable hepatocellular carcinoma.
Thus, the approach of TACE is a palliative treatment to
control tumor growth [8-13].
In recent studies, some parameters, such as tumor size,
portal invasion, alpha fetoprotein (AFP), Child-Pugh score,
bilirubin, ascites, and performance status were found to
have prognostic and predictive impact if determined prior
to TACE [14]. Yet, there are still no accepted parameters
to evaluate the early therapy response after TACE. How-
ever, these predictive and prognostic markers are impor-
tant as the early modification of the treatment strategy
could potentially save time as well as costs. Recently,
various techniques, such as computed tomography (CT)
or magnetic resonance imaging (MRI), have demonstrated
to be able to indicate insufficient response to therapy
within one or two month [15-17]. In addition, the course
of the apparent diffusion coefficient (ADC) in MRI before
and after TACE is supposed to monitor therapy response
within several days after treatment [18,19]. However,
further easily obtainable sensitive and robust markers are
required to efficiently monitor TACE treatment. Most
promising candidates are biochemical markers circulating
in the blood that are related to the disease and therapy as
they can be measured non-invasively and cost-effectively,
also in serial determinations.
In lung cancer, cell death markers, such as nucleo-
somes and cytokeratin-19 fragments (CYFRA 21-1), have
been identified as relevant biochemical markers enabling
early estimation of systemic chemotherapy efficacy
[20,21]. In the present study, we investigated these mar-
kers, the HCC-associated marker AFP and other liver
enzymes to identify pre- or post-treatment variables that
may anticipate therapy response already in the early
treatment phase.
Methods
Patients
In the present study cohort, 50 patients suffering from
hepatocellular cancer (42 males and eight females, mean
age 66.7 years) were prospectively and consecutively
included. All patients were diagnosed and staged at the
University Hospital Munich-Grosshadern between 2006
and 2008. Patient characteristics are summarized in
Table 1 (Table 1). Diagnosis of HCC was confirmed by
fine needle biopsy or radiological criteria (two coinci-
dent imaging techniques) or combined criteria (one ima-
ging technique associated with elevated AFP levels
according to the Barcelona EASL Conference 2000 cri-
teria) [22]. The study was approved by the local ethics
Table 1 Characteristics of patients with hepatocellular
cancer
Median Range
Age 66.7 45.1 - 83.7
Survival 14.5 1.1 - 25.1
Number Percentage (%)
Total 50 100
Gender
Female 8 16.0
Male 42 84.0
Cirrhosis 37 74.0
Child-Pugh stage
A 20 40.0
B 14 28.0
C 3 6.0
Risk factors
Hepatitis B positive 2 4.0
Hepatitis C positive 8 16.0
HBV + HCV 3 6.0
Alcohol-induced cirrhosis 21 42.0
Alcohol + HCV 1 2.0
Number of tumors
single lesion 13 26.0
double lesions 8 16.0
multiple lesions 29 58.0
Tumor size
≤ 1 cm 2 4.0
≤ 3 cm 14 28.0
≤ 5 cm 17 34.0
≤ 10 cm 13 26.0
> 10 cm 4 8.0
T-stage
T1 10 20.0
T2 4 8.0
T3 36 72.0
Treatments before TACE
Resection 5 10.0
PEI 2 4.0
Indication of TACE
Palliative 33 66.0
Bridging 5 10.0
bridging (plus RFA) 1 2.0
palliative (plus RFA) 5 10.0
palliative after prior resection 5 10.0
Treatments after TACE
TACE 21 42.0
Sorafenib 7 14.0
TACE and Sorafenib 4 8.0
LTX 6 12.0
Time of study entry
1st application 21 42.0
2
nd-further application 29 58.0
Total therapies 77 100
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from each patient before first blood sampling.
Treatment procedures
All TACE procedures were performed under angio-
graphic control (Multistar TOP and Axiom Artis dTA,
Siemens, Munich, Germany) and local anesthesia. After
inserting a 4-French (Fr) pigtail catheter into the femoral
artery via micro incision into the groin, panviscerography
was performed to detect potentially aberrant or addi-
tional hepatic and possibly tumor-feeding arteries. After
identifying the tumor-feeding arteries, a 4-Fr catheter
(e.g. cobra configuration) for selective use or a superse-
lective microcatheter, which could be placed through the
primary 4-Fr catheter, were directed as close as possible
to the tumor-feeding vessels. The embolizing moiety was
prepared by extensive mixing between two syringes, typi-
cally consisting of 3-5 ml lipiodol, microparticles of
150-500 μm( e . g .C o n t o u rS E
®, Boston Scientific, Ratin-
gen, Germany) and farmorubicin (1 mg/kg b.w.). Subse-
quently, the embolizing agent was slowly injected under
fluoroscopic control to avoid retrograde embolization of
non-target areas due to back spill. The injection was
s t o p p e da ss o o na ss t a s i sw ithin the tumor vessels
occurred. Treatment was terminated if a flow within the
tumor vessels was no longer detectable after 5-10 min.
Otherwise, another injection was performed. In case of
several main feeders, vessels were treated subsequently.
Classification of response to therapy
In all patients, staging investigations, consisting of
abdominal CT or MRI and laboratory examinations,
were performed prior to the next TACE therapy. The
median evaluation time of therapy response was 70 days
(range: 22 - 216 days) after TACE. The response to
therapy was classified according to RECIST criteria for
solid tumors defining ‘complete remission’ as complete
disappearance of all such manifestations of disease, ‘par-
tial remission’ as reduction of tumor diameter ≥ 30%,
‘progression’ as tumor increase ≥ 20% or appearance of
new tumor manifestations, and ‘stable disease’ as tumor
reduction < 30% or increase < 20% in medical imaging
[23].
Sample collection and assays
Blood samples were collected prospectively prior to
TACE, and three, six and 24 hours (h) after TACE. We
performed the preanalytical handling of the samples as
described in Holdenrieder et al. [24]: Blood samples
w e r ec e n t r i f u g e da t3 , 0 0 0×Gf o r1 5m i nw i t h i no n et o
two hours after venipuncture. Subsequently, serum sam-
ples were stabilized by adding 10 mM EDTA and stored
at -80°C. Prior to measurement of nucleosomes, samples
were thawed, homogenized and diluted 1:4 with an
incubation buffer. The courses of nucleosomes of single
patients were determined within one run of the enzyme
immunoassay to minimize methodical variance.
Quantification of nucleosome concentrations in serum
was done by use of Cell Death Detection Elisa
plus of Roche
Diagnostics (Mannheim, Germany). Two monoclonal
mouse antibodies, directed against histones and DNA,
respectively, specifically catch the nucleosomes. While the
anti-histone antibodies fix the complexes to the microtiter
plate, the anti-DNA antibodies, which are labeled with
peroxidase, react with the added 2,2’-azino-di-(3-ethyl-
benzthiazolin-sulfonate) substrate. The resulting color
development is proportional to the amount of nucleo-
somes captured in the antibody sandwich. This enables
photometric quantification of nucleosomes in ng/mL
according to an established standard curve.
In addition, we determined CYFRA 21-1 and AFP by
Elecsys 2010 (Roche Diagnostics, Mannheim, Germany)
and lactate dehydrogenase (LDH), C-reactive protein
(CRP), aspartate-aminotransferase (AST), alanine-amino-
transferase (ALT), glutamate dehydrogenase (GLDH),
bilirubin, gamma-glutamyl-transferase (GGT), alkaline
phosphatase (AP), amylase, lipase and choline esterase
(CHE) by high-end analyzer AU 2700 (Olympus Diagnos-
tics, Hamburg, Germany) in all serum samples.
Statistics
Concentrations of all measured markers prior to and
three, six and 24 hours after TACE as well as their per-
cental changes were considered for statistical evaluation.
Concerning their response to therapy, partial remission
and stable disease were assigned to the ‘no progression’
group. They were compared with patients who suffered
Table 1 Characteristics of patients with hepatocellular
cancer (Continued)
Therapy
TACE 71 92.2
TACE + RFA 6 7.8
Number of TACE cycle
1 21 29.6
2 20 28.2
3 16 22.5
4 7 9.9
≥5 7 9.9
Time of CT- and MRI-Scan after TACE
< 60 days 20 28.2
60 - 90 days 36 50.7
> 90 days 15 21.1
Therapy response (TACE alone)
REM 2 2.8
SD 30 42.3
PD 39 54.9
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accompanied by RFA treatment the following day these
were excluded from the evaluation of therapy response
due to confounding effects.
Wilcoxon test was applied for comparison of marker
concentrations between the two groups in relation to
therapy response. The influence of TACE cycle number
on marker values (cycle 1 vs cycles ≥2; and cycles 1+2
vs cycles > 3) was also calculated by Wilcoxon test;
influence of TACE cycle number on therapy response
was tested by Mantel-Haenszel-Chi-Square test; associa-
tion of T-stage (T1+2 vs T3) on therapy response was
analyzed by Chi-Square test. Univariately relevant mar-
kers indicating therapy response (after logarithmizing to
the basis 2) and clinical factors were included in a mul-
tivariate logistic regression analysis to identify the best
prediction model.
A p-value of < 0.05 was considered statistically signifi-
cant. All calculations were performed with SAS software
(version 9.2, SAS Institute Inc., Cary, N.C., USA).
Results
In the present study, 50 patients with a total of 77
TACE treatments were evaluated. After exclusion of six
treatments due to subsequent RFA treatment, 71 treat-
ments were evaluated for their response to TACE
according to staging by imaging after approximately two
months (median 70 days). In these imaging investiga-
tions, 32 TACE-treatments out of 71 showed stable dis-
ease (N = 30) or partial remission (N = 2) after TACE
(no progression), while the remaining 39 treatments
showed progressive disease. In 21 cases, first cycle of
TACE was applied, while in 50 cases, the second or
later TACE cycles were applied. Details of patient char-
acteristics are listed in Table 1 (Table 1).
Kinetics of the markers
As early as 24 h after application of TACE, concentra-
tions of circulating nucleosomes, CYFRA 21-1, LDH,
CRP, bilirubin, and activity of liver enzymes were
increased in most patients. In contrast, median activities
of pancreas enzymes lipase, amylase and alkaline phos-
phatase (AP), and choline esterase, as well as concentra-
tion of AFP were decreased or stable when compared to
pretherapeutic values (Table 2 and Figure 1).
Correlation with therapy response
Although pretherapeutic values of circulating nucleosomes
were not different in both responder groups, higher values
of circulating nucleosomes were measured 24 h after treat-
ment in patients with progressive disease compared to non
progressive patients (p = 0.002). In consequence, the per-
cental changes of circulating nucleosomes between pre-
therapeutic values and 24 h values were significantly
greater in the progressive group (p < 0.001). Interestingly,
3 h and 6 h values were temporarily decreased in many
patients.
The other two cell death parameters LDH and CYFRA
21-1 were increased 24 h after treatment with no signifi-
cant differences between both groups. However, 3 h and 6
h after TACE, CYFRA 21-1 values showed slightly signifi-
cant differences (p = 0.041). Just as nucleosomes, CYFRA
21-1 showed decreasing values in both groups after 3 h
and 6 h, whereby responders had decreasing levels more
o f t e nt h a nn o n - r e s p o n d e r s .Further markers which dif-
fered in the two response groups before and 24 h after
T A C Ew e r eA F P ,G G T ,A Pa sw e l la sA L T3ha n d6h
after TACE (Table 3 and Figure 2).
Concerning clinical factors, T1 and T2 tumors were
associated with better response to therapy when com-
pared to T3 stage disease (p = 0.191). Also, the number
of TACE cycles correlated with poor response (p =
0.0266). Importantly, the number of TACE cycles did not
correlate with levels of markers associated with treatment
r e s p o n s e ,p a r t i c u l a r l yn u c l e o s o m e s ,A F P ,G G T ,A Pa n d
ALT. Notably, therapy response correlated with overall
survival of the patients as well underlining its relevance
as a meaningful endpoint (p = 0.019).
All univariately relevant biochemical markers measured
before (0 h) and 24 h after TACE indicating later therapy
response were logarithmized and included, together with
clinical factors, into a multivariate logistic regression ana-
lysis. Next, the best model of independent predictive mar-
kers was identified as combination of nucleosomes (24 h),
AP (24 h) and TACE cycle number (Table 4). A similar
predictive strength, objectified by Akaike information cri-
terion, was achieved when AP (24 h) was replaced by AFP
(24 h). The area under the curve (AUC) of the receiver
operating characteristic (ROC) curves for estimation of
non-response to therapy was considerably improved when
using the risk score based on the combination model
(AUC 81.8%) as compared to the single marker nucleo-
somes (24 h; 71.4%) and AP (24 h; 69.2%; Figure 3). The
resulting sensitivities for prediction of non-response to
therapy were 41% at 97% specificity, and 72% at 78% speci-
ficity using the risk score.
Discussion
Diagnosis of hepatocellular carcinoma is often only per-
formed in advanced stages of the disease due to the late
appearance of symptoms. In recent years, the introduc-
tion of screening programs in patients with major risk
factors has resulted in earlier diagnosis of HCC. How-
ever, many patients are still diagnosed at a late stage
when treatment in curable intention is no longer an
option [6,25]. In HCC patients considered unsuitable
candidates for surgery or ablative therapies, TACE is the
most widely used treatment option and it has recently
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Page 4 of 10Table 2 Levels of biomarkers before, 3 h, 6 h, and 24 h after application of TACE (medians; ranges; p-values for
changes from 0 h)
0h 3h 6h 2 4h
Nucleosomes (ng/mL) 97.8 69.8 66.4 139.3
(10.0 - 846.0) (10.0 - 1861.3) (13.0 - 660.1) (11.9 - 1116.5)
0.067 0.121 0.007
AFP (ng/mL) 5.9 5.5 5.8 5.4
(0.8 - 71221.0) (0.9 - 73955.0) (0.9 - 82861.0) (0.9 - 70228.0)
0.032 0.086 0.553
CYFRA 21-1 (ng/mL) 1.8 1.7 1.6 2.0
(0.5 - 20.9) (0.5 - 21.6) (0.5 - 22.1) (0.6 - 31.0)
0.702 0.017 0.003
LDH (U/L) 200.0 199.0 204.5 240.0
(139.0 - 403.0) (137.0 - 412.0) (136.0 - 391.0) (155.0 - 1062.0)
0.958 0.351 < 0.001
CRP (mg/dL) 0.5 0.5 0.6 1.4
(0.1 - 10.5) (0.1 - 11.7) (0.1 - 12.4) (0.1 - 13.3)
0.802 0.262 < 0.001
AST (U/L) 49.0 51.0 53.5 90.0
(18.0 - 238.0) (20.0 - 263.0) (18.0 - 248.0) (30.0 - 710.0)
0.063 < 0.001 < 0.001
ALT (U/L) 38.0 38.0 40.0 60.0
(12.0 - 179.0) (15.0 - 190.0) (16.0 - 198.0) (21.0 - 740.0)
0.083 0.313 < 0.001
GLDH (U/L) 6.6 5.9 6.5 16.8
(1.0 - 42.3) (1.0 - 36.2) (1.0 - 33.9) (1.5 - 206.0)
0.065 0.574 < 0.001
Bilirubin (mg/dL) 0.9 1.2 1.2 1.5
(0.3 - 6.1) (0.3 - 7.3) (0.3 - 7.2) (0.5 - 9.5)
< 0.001 < 0.001 < 0.001
GGT (U/L) 156.0 153.0 161.0 168.0
(25.0 - 1007.0) (22.0 - 888.0) (23.0 - 911.0) (25.0 - 930.0)
< 0.001 0.092 0.001
AP (U/L) 128.0 113.0 124.0 124.0
(58.0 - 421.0) (57.0 - 408.0) (54.0 - 416.0) (62.0 - 468.0)
< 0.001 < 0.001 0.221
Amylase (U/L) 82.0 80.0 81.5 77.0
(24.0 - 839.0) (19.0 - 773.0) (20.0 - 821.0) (24.0 - 829.0)
< 0.001 0.322 0.131
Lipase (U/L) 42.0 36.0 36.5 34.0
(9.0 - 342.0) (8.0 - 149.0) (6.0 - 127.0) (8.0 - 188.0)
< 0.001 0.061 < 0.001
CHE (kU/L) 4.4 4.4 4.5 4.4
(0.9 - 8.8) (0.8 - 9.4) (0.9 - 8.8) (0.9 - 9.7)
0.563 0.840 0.002
Urea (mg/dL) 33.0 33.0 35.5 35.0
(16.0 - 87.0) (17.0 - 79.0) (16.0 - 81.0) (17.0 - 89.0)
0.079 0.316 0.014
Uric acid (mg/dL) 5.9 6.2 6.1 6.0
(3.2 - 10.7) (3.2 - 10.9) (3.4 - 10.9) (3.5 - 10.9)
0.011 0.018 0.438
Creatinine (mg/dL) 0.9 0.9 1.0 1.0
(0.6 - 1.6) (0.5 - 1.7) (0.5 - 1.7) (0.6 - 1.8)
0.001 0.393 0.201
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Page 5 of 10been shown to improve survival in comparison to best
supportive care [8-13].
It is known that in tumor tissue, massive cell prolifera-
tion and cell death often coexist at the same time. This
turnover of cells, including the release of apoptotic pro-
ducts like circulating nucleosomes, varies between differ-
ent kinds of cancers and also between individuals [26].
Also in hepatocellular carcinoma, dysregulation of the
balance between proliferation and cell death has been
found. Downregulation of proapoptotic molecules, such
as p53, and upregulation of antiapoptotic markers, such
as NF-B, may - inter alia - be responsible for this imbal-
ance [27]. Nevertheless, the apoptosis index was found to
be higher in advanced tumor stages and in patients with
metastasis. This is possibly due to the increasing amount
of dysfunctional cells [28]. As HCC is often diagnosed in
advanced stages and circulating nucleosomes are markers
for cell death, we expected to find high rates of nucleo-
somes pretherapeutically as well as during therapy. The
pretherapeutic median value of nucleosomes was higher
than in healthy individuals (36 ng/mL) [29]. Subse-
quently, values temporarily declined in most patients 3 h
and 6 h after therapy, followed by a rapid increase after
24 hours. However, comparison of patients with T-stages
1 and 2 disease versus T3-stage disease revealed no sig-
nificant difference between both groups. This is in line
with earlier findings in pancreatic and colorectal cancer
during systemic radiochemotherapy and may be
explained by cell cycle arrest and repair processes which
occur during the early phase after cellular and chromatin
damages [30,31]. Furthermore, the cell death biomarkers
CYFRA 21-1 and LDH, the liver enzymes ALT, AST, and
GLDH as well as cholestasis parameters such as bilirubin
and GGT also increased 24 hours after therapy.
C
R
P
 
[
m
g
/
d
L
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Praether.
N=77
3 h
N=77
6 h
N=76
24 h
N=77
N
u
k
l
e
o
s
o
m
e
n
 
H
S
 
[
n
g
/
m
l
]
    10
   100
  1000
 10000
Praether.
N=77
3 h
N=77
6 h
N=76
24 h
N=76
C
Y
F
R
A
 
2
1
-
1
 
[
n
g
/
m
l
]
    0.1
    1.0
   10.0
  100.0
Praether.
N=77
3 h
N=77
6 h
N=76
24 h
N=77
A
F
P
 
[
n
g
/
m
l
]
    0.1
    1.0
   10.0
  100.0
 1000.0
10000.0
 100000
Praether.
N=77
3 h
N=77
6 h
N=76
24 h
N=77
N
u
c
l
e
o
s
o
m
e
s
 
(
n
g
/
m
L
)
C
R
P
 
(
m
g
/
d
L
)
A
F
P
 
(
n
g
/
m
L
)
C
Y
F
R
A
 
2
1
-
1
 
 
(
n
g
/
m
L
)
0h
N=77
3h
N=77
6h
N=76
24h
N=76
0h
N=77
3h
N=77
6h
N=76
24h
N=77
0h
N=77
3h
N=77
6h
N=76
24h
N=77
0h
N=77
3h
N=77
6h
N=76
24h
N=77
A)
C) D)
B)
Figure 1 Box-plots of serum levels of nucleosomes, cytokeratin-19 fragments (CYFRA 21-1), alpha fetoprotein (AFP), and C-reactive
protein (CRP) showing medians, interquartile ranges, minimum and maximum in all patients during the first day after TACE (★
indicate significant changes from 0 h values).
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Page 6 of 10As macroscopic changes in tumor volume often occur
only some time after the application of cytotoxic thera-
pies and as their measurement is cost-intensive, bio-
chemical diagnostic tools are required to provide an
earlier and less expensive estimation of therapy efficacy
and to enable, if possible, effective modification or inten-
sification of therapy, e.g. with sorafenib or other targeted
agents [32]. In our setting, indication of therapy response
by circulating nucleosomes measured after 24 h was
highly significant. Responders to therapy had decreasing
levels of circulating nucleosomes 24 h after chemoembo-
lization, while non-responders showed increasing levels.
In consequence, percental changes of circulating nucleo-
somes pretherapeutically and 24 h after TACE were sig-
nificantly different. It can be speculated that the observed
increases of circulating nucleosome levels in patients
with no response to chemotherapy is caused by the pre-
sence of more aggressive and larger tumors. Further-
more, the efficiency of the local immune system may be
limited in patients with advanced tumors leading to a
delayed local and plasmatic elimination of liberated
nucleosomes [29].
Interestingly, several biochemical liver parameters
showed significant differences in the response groups:
Table 3 Correlation of biomarkers with therapy response
Marker Time Response N = 32 No-Response N = 39 P-Value
Nucleosomes (ng/mL) 0 h 107.5 80.7 0.142
24 h 81.8 231.1 0.002
pc. -26.2 114.3 < 0.001
AFP (ng/mL) 0 h 4.4 7.9 0.011
24 h 4.2 7.9 0.010
pc. 0 0 0.822
CYFRA 21-1 (ng/mL) 0 h 1.8 2.0 0.349
24 h 2.0 2.2 0.101
pc. 0 14.3 0.229
LDH (U/L) 0 h 198.5 200.0 0.288
24 h 240.0 250.0 0.746
pc. 21.6 21.0 0.712
CRP (mg/dL) 0 h 0.4 0.8 0.424
24 h 1.2 1.5 0.361
pc. 100.0 133.3 0.644
CHE (kU/L) 0 h 4.4 4.4 0.636
24 h 4.6 4.4 0.652
pc. 3.0 4.6 0.514
AST (U/L) 0 h 41.5 56.0 0.084
24 h 101.0 89.0 0.556
pc. 102.6 50.0 0.241
ALT (U/L) 0 h 37.5 38.0 0.652
24 h 63.5 57.0 0.138
pc. 72.6 19.8 0.051
GLDH (U/L) 0 h 5.0 7.7 0.150
24 h 12.7 18.4 0.922
pc. 151.7 90.0 0.280
Bilirubin (mg/dL) 0 h 0.9 1.0 0.276
24 h 1.5 1.6 0.231
pc. 47.7 60.0 0.995
GGT (U/L) 0 h 109.0 192.0 0.034
24 h 108.5 206.0 0.027
pc. 2.8 5.7 0.234
AP (U/L) 0 h 119.5 140.0 0.023
24 h 112.5 143.0 0.006
pc. -4.1 1.9 0.317
Median values and p-values (Wilcoxon-test) are shown for the two response groups (pc. = percental changes)
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Page 7 of 10AFP, AP and GGT were elevated before and 24 h after
TACE in patients who suffered from less efficient
therapies.
Some patients were enrolled not at their first but at a
later TACE treatment. As it was observed that first or
second applications of TACE were associated with bet-
ter outcome when compared with later therapies,
influence of cycle number on biomarker values was
assessed. However, at least for the meaningful predictive
markers, no association with treatment cycle number
was found.
As several biomarkers measured before (0 h) and 24 h
after TACE have been identified to indicate later therapy
response in univariate analyses, they were included with
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Figure 2 Dot-plots of serum levels of nucleosomes, alkaline phosphatase (AP), alpha fetoprotein (AFP) and gamma-glutamyl-
transferase (GGT) with respective medians of patients with response to therapy (○) and those with no response to therapy (●) for all
time points during the first day after TACE (★ indicate significant differences).
Table 4 Best multivariate model of independent predictive biochemical and clinical markers for poor efficacy of TACE
therapy
Parameter Coefficient Odds-Ratio 95%-Conf. Interval Chi-Square P-value
Nucleosomes
(24 h, log2)
0.581 1.79 1.20 - 2.66 8.25 0.0041
Alkaline
Phosphatase
(24 h, log2)
1.561 4.76 1.45 - 15.64 6.62 0.0101
Number of
TACE cycle
0.636 1.89 1.18 - 3.02 7.08 0.0078
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Page 8 of 10clinical factors in a multivariate logistic regression analy-
sis. Thus, the combination of nucleosomes (24 h), AP
(24 h) and TACE cycle number was found to be the
best model of independently predictive markers, while
replacement of AP with AFP led to quite similar results.
It has to be pointed out that markers were included into
the model on a logarithmic scale to the basis 2 in order
to avoid too optimistic cutoff definitions and overfitting
to the sample. In consequence, any doubling of the mar-
ker values was associated with a relative risk of 1.79 for
nucleosomes and 4.76 for AP for non-response to
therapy.
Using the risk score based on the proposed combina-
tion model, the AUC in ROC curves and the respective
sensitivities at defined specificities were considerably
improved in comparison with the use of only single
markers. Notably, a sensitivity of 41% for prediction of
non-response to therapy was obtained at 97% specificity,
and a 72% sensitivity at 78% specificity. As TACE cycle
numbers were included into the multivariate model this
would be applicable independently regardless whether
the first or a later TACE treatment is applied.
Obviously, the present study has some drawbacks,
such as the limited number of patients and the scatter
in the intervals of determining therapy response.
Although most patients had been screened prior to their
next TACE treatment or at radiological control exams
60 to 90 days after TACE treatment, some exceptions
ocurred, such as the case of one patient who died 22
days after TACE due to the cancer disease. This patient
was therefore classified as non-responder. Another
patient did not return to hospital due to his good physi-
cal condition and was only staged after 216 days. In
total, there were four patients with staging intervals of
more than four months. Two of these patients
responded well to therapy.
It has to be emphasized that all patients were included
in the study prospectively and with no other than the
indicated selection criteria in order to enable narrow-
meshed blood sampling, control of the preanalytics and
to guarantee completeness of data.
Conclusions
Overall, our results demonstrate the high relevance of
circulating nucleosomes and other liver markers in addi-
tion to clinical parameters for early estimation of the
later response to TACE therapy in HCC patients. The
model of nucleosomes (24 h), AP (24 h) and TACE
number is recommended for further validation in clini-
cal trials.
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